Replies to post #736451 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

George,

The first 35 patients in the neoadjuvant trial were enrolled between October 2016 and September 2017. That was quite a while ago.

See the following figure which is about the data on the 25 rGBM patients? But there is an extra column and it is the first column which is the data on patient #7 from the 35 patients. I suspect that Merck enrolled another 25 rGBM patients in 2020 with the objective in making a better comparison with the data from the combo trial in 2020.

Can we conclude that DCVax L could/did enhance Pembros MOA based on the additional 25?

100%. We can have a sense from the following figure. More importantly, for the combo trial, we know the root cause that affects the efficacy. It is the immunosuppression from TAMs.